SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biote

Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular ses

Nathaniel Bradley, Co-Founder and CEO of Datavault AI Inc. (NASDAQ:DVLT), presents today, Tuesday, S

Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington

Investment led by Clene's Chairman of the Board of Directors, alongside founding investor Kensington

Canopy Growth (NASDAQ: CGC - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both sm

SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that ma

Clene NASDAQ: CLNN is preparing to submit a New Drug Application, or NDA, seeking accelerated approv

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media p

SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that man

Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estima

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pa

Clene NASDAQ: CLNN said it is preparing to submit a new drug application, or NDA, in early fourth qu

SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidia

Clene (CLNN) appears to have found support after losing some value lately, as indicated by the forma

Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estim

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.69) per share which missed the analyst consensu

After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® unde

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiar

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiar

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and ma

Clene Inc. (NASDAQ:CLNN) shares are up 6.68% on Monday as the company is filing for accelerated appr

FDA signals accelerated pathway for Clene's ALS drug CNM-Au8, with NDA filing planned and mixed

Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels hig

Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidi

FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 7,748 shares of

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,374 shares of

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.88) per share which missed the analyst consensu

The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent ana

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") an

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") an

Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidi

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.85) per share which missed the analyst consensu

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ: CLNN) with a Buy and maintains $2

Benchmark analyst Bruce D. Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price

Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's abilit

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23

Canaccord Genuity analyst Sumant Kulkarni maintains Clene (NASDAQ:CLNN) with a Buy and lowers the

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.78) per share which missed the analyst consensu

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23